OneChain Immunotherapeutics
Time 2022-08-16 20:41:56Web Name: OneChain Immunotherapeutics
WebSite: http://www.onechaintx.com
ID:283742
Keywords:
OneChain,ImmunotherapeuticsDescription:
OneChain Immunotherapeutics is a spin-off company from the Josep Carreras Leukemia Research Institute and ICREA, based on research led by Dr. Pablo Menéndez. OneChain aims to develop CAR-T candidates as a treatment for oncological diseases.
Pipeline
OC_1
CART CD1a Immunotherapy against T-ALL
T-ALL comprises 10–15% of all acute leukemias diagnosed in children and 20–25% in adults, with a median diagnostic age of 9 years. Survival of patients with T-ALL treated with intensive chemotherapy remains less than 70%, and relapsed/refractory (r/r) T-ALL has a particularly poor outcome of 6% to 20% in 5 to 10 years. OC_01 is a CART CD1a Immunotherapy developed as a treatment for refractory relapsed patients with cortical T-ALL, a T-ALL subgroup without many options to date.
OC_2
CART CD22 Immunotherapy
B-ALL is the most common cancer in children and despite current 5-year disease-free survival rates of 80%, relapsed/refractory (r/r) patients still have a dismal outcome. B-ALL is less frequent in adults and still associated with unfavorable clinical outcomes. OC_02 immunotherapy, based on a bispecific CART, is an alternative treatment to salvage chemotherapy followed by autologous stem cell transplantation only suitable for 50% of eligible patients with r/r B-ALL.
OC_3
Novel γδ T cells allogeneic platform
Recently, γδ T cells have emerged as an alternative to αβ T cells for cellular immunotherapy. They are not constrained by MHC presentation of tumor‐associated peptides but, providing robust and durable antitumor responses. OneChain platform is a novel and efficient method for a selective, large‐scale generation of human cytotoxic Vδ1+ γδ T cells. They are very attractive candidates for adoptive cell therapy of cancer. Vδ1 naïve cells are produced in a TCR-independent manner and expanded to induce Vδ1+ T cell proliferation, which allows for a significant-fold expansion.
Stage of Development
ProductIndicationDevelopmentPreclinicalClinicalOC_1 T-ALL
OC_2 B-ALL
OC_3 Allogeneic
Vision
To create a better, healthier world for people with cancer
Mission
To discover, develop and deliver innovative therapeutics for patients suffering from leukemia
Core Values
IntegrityDoing What’s RightTeamworkWorking TogetherAccountabilityTaking Personal ResponsibilityExcellenceBeing Your BestBoard of directors
Pablo Menéndez
Founder and CSO
Pablo Menéndez was awarded a PhD by the University of Salamanca in 2002. He then conducted postdoctoral training (2002-2006) in stem cell biology and childhood leukemia. He returned to Granada as Director of The Andalusian Stem Cell Bank and Principal Investigator at GENyO, a Pfizer-Andalusian Health Department centre for Genomics and Oncology (2007-2013). Since July 2013 he is an ICREA Research Professor and he heads the "Stem cell biology, developmental leukemia and Immunotherapy" group at the Josep Carreras Leukemia Institute-Campus Clinic Hospital-School of Medicine of the University of Barcelona. Pablo Menendez has published 190 peer-review publications with an accumulated impact factor of 1600 (H and i10 factors are 54 and 140, respectively). His work has been cited 10500 times. He has obtained solid competitive national and international research funding, has filed 10 patents in stem cell biology and immunotherapy, and has supervised >30 scientific staff including master, PhD students, postdoctoral scientists and technicians.
Albert Carreras
Trustee of Josep Carreras Foundation
Lawyer, entrepreneur and trustee of Josep Carreras International Leukaemia Foundation. In 2010, this non-profit organization launched a ground-breaking project: the Josep Carreras Leukaemia Research Institute, the first European research center exclusively focused in leukaemia and other haematological diseases, and one of the few existing in the world
Luís Pareras
Partner InVivo Capital
Luis is an entrepreneur in the healthcare space and founder and partner of Invivo Capital Partners together with Albert Ferrer. He is or has been board member of biotech start-ups Versantis, Peptomyc, Sanifit, Minoryx, N-life, Arthex Biotech, Pulmobiotics, Gyala, Telum Therapeutics, OneChain Immunotherapeutics and Telomere Therapeutics, and advisor to a number of biotechnology and innovation organizations.
Albert Ferrer
Partner InVivo Capital
Degree in Business Administration and MBA from ESADE, Master CEMS in HEC Paris and Chartered Financial Analyst (CFA). He has been involved in the Spanish VC industry for the past 15 years in several companies. Specialist in corporate transactions and asset valuation. He sits in the board of several Life Sciences companies. Founded Invivo Capital Partners together with Luis Pareras.
Jorge Alemany
CEO
Jorge has a long experience in research and management in prestigious institutions such as the NIH in the USA or at the Nactional Cancer Center (CNIO) in Spain. He has work in PharmaGen (today Genómica SAU.), Genetrix and Spherium Biomed. Founder of Cellerix, later Tigenix, that was acquired by Takeda Pharmaceuticals in 2018. Cellerix developed the first Cell Therapy product approved by the EMA.
Team
Pablo Menéndez
Founder and CSO
Pablo Menéndez was awarded a PhD by the University of Salamanca in 2002. He then conducted postdoctoral training (2002-2006) in stem cell biology and childhood leukemia. He returned to Granada as Director of The Andalusian Stem Cell Bank and Principal Investigator at GENyO, a Pfizer-Andalusian Health Department centre for Genomics and Oncology (2007-2013). Since July 2013 he is an ICREA Research Professor and he heads the "Stem cell biology, developmental leukemia and Immunotherapy" group at the Josep Carreras Leukemia Institute-Campus Clinic Hospital-School of Medicine of the University of Barcelona. Pablo Menendez has published 190 peer-review publications with an accumulated impact factor of 1600 (H and i10 factors are 54 and 140, respectively). His work has been cited 10500 times. He has obtained solid competitive national and international research funding, has filed 10 patents in stem cell biology and immunotherapy, and has supervised >30 scientific staff including master, PhD students, postdoctoral scientists and technicians.
Jorge Alemany
CEO
Jorge has a long experience in research and management in prestigious institutions such as the NIH in the USA or at the Nactional Cancer Center (CNIO) in Spain. He has work in PharmaGen (today Genómica SAU.), Genetrix and Spherium Biomed. Founder of Cellerix, later Tigenix, that was acquired by Takeda Pharmaceuticals in 2018. Cellerix developed the first Cell Therapy product approved by the EMA.
Wilmar Castillo Ávila
Project Manager
Wilmar has more than 15 years of biomedical research experience at the University of Barcelona, the pharmaceutical company Ferrer and the Catalan Institute of Oncology. During the last 6 years, she has focused her work on managing pharmaceutical development projects in different therapeutic areas in companies such as AlbaJuna Therapeutics SL and Spherium Biomed SL. As a project manager, she has led and coordinated multifunctional teams to ensure preclinical and clinical projects' progress.
Víctor M. Díaz Cortés
Research Director
With more than 15 years in biomedical and oncological research at the Autonomous University of Barcelona, the Hospital de la Vall d'Hebron, the New York University School of Medicine and the San Raffaele Biomedical Science Park in Milan, and the IMIM-Hospital del Mar. After completing his postdoctoral training, he joined the Universitat Pompeu Fabra as a full professor and later as an assistant, and has recently joined the International University of Catalonia.
Laura García Pérez
Scientist
Biologist graduated at the University of Granada, she did her PhD in Immunology at the section of Molecular Gastroenterology and Immunology of the University Medical Center Hamburg-Eppendorf and the Immunobiology department at Yale University. Her research has focused on the role of T-cell derived cytokines in the context of intestinal inflammation and carcinogenesis. After her first postdoctoral training at the University Medical Center Hamburg-Eppendorf, she is joining OneChain Immunetherapeutics as Scientist
Press & Media
(Spanish) Invivo Ventures, CDTI-Innvierte y la Fundación Josep Carreras cierran una ronda de financiación de 3.050.000€ en OneChain Immunotherapeutics
Press(Spanish) Fundación Carreras crea 'spin-off' para desarrollar terapia inmunooncológica
Press Tweets by OneChainTXInvestors
Contact
info@onechaintx.com609 149 992Google MapsOffice
C/Muntaner 383, 3rd 2nd 08021 BarcelonaSpain
Google MapsLaboratoryJosep Carreras Institute Campus Clinic LaboratoriesAla Sud, 2nd section, 4th floorFaculty of Medicine of the University of BarcelonaC. Casanova 14308036 Barcelona
Write us an emailinfo@onechaintx.com
TAGS:OneChain Immunotherapeutics
<<< Thank you for your visit >>>
Websites to related :
adsHot Websites